Antibody-drug conjugates: design and clinical progress
Wang, Y.-j.; Cao, X.; Liu, X.-y.; Lu, X.-l.; Li, Y.-y.; Jiao, B.-h.
Yao Xue Xue Bao 51(8): 1209-1216
2016
ISSN/ISBN: 0513-4870 PMID: 29897715 Document Number: 688156
Antibody-drug conjugates, constructed with monoclonal antibodies, linker and cytotoxins, have distinctive advantages over chemotherapy drugs and antibody drugs in cancer therapy. In this review, the strategy of developing ADCs, and the important progress in past decade are well summarized. The representative ADCs in the pipeline are introduced and characterized with their new features. While, perspective for future directions of ADCs is proposed.
Document emailed within 1 workday
Related Documents
Guo, J.-j.; Gao, R.; Quan, T.-f.; Zhu, L.-y.; Shi, B.; Zhao, Y.-y.; Zhu, J.; Li, M.-s.; Bu, H.-z. 2015: Progress on pharmacokinetic study of antibody-drug conjugates Yao Xue Xue Bao 50(10): 1203-1209Smyth, M.J.; Pietersz, G.A.; McKenzie, I.F. 1987: Use of vasoactive agents to increase tumor perfusion and the antitumor efficacy of drug-monoclonal antibody conjugates Journal of the National Cancer Institute 79(6): 1367-1373
Starling, J.J.; Hinson, N.A.; Marder, P.; Maciak, R.S.; Laguzza, B.C.; Corvalan, J.R.; Smith, W. 1988: Development of a dual label fluorescence technique that can be utilized to elucidate the mechanism of action of monoclonal antibody-drug conjugates Cancer Research 48(21): 6211-6216
Neal, B.; MacMahon, S. 1995: PROGRESS (perindopril protection against recurrent stroke study): rationale and design. PROGRESS Management Committee [corrected Journal of Hypertension 13(12 Pt 2): 1869-1873
Sokolova, M.V.; Pomelova, V.G.; Chudinov, A.V.; Gaĭdamovich, S.I.; Leonov, S.V.; Kharitonenkov, I.G.; Bychenkova, T.A.; Busel, E.P.; Zlobin, V.N. 1991: The design and trial of conjugates for performing lanthanide immunofluorescence analysis Voprosy Virusologii 36(2): 140-142
Twum-Danso, N.A.Y.; Akanlu, G.B.; Osafo, E.; Sodzi-Tettey, S.; Boadu, R.O.; Atinbire, S.; Adondiwo, A.; Amenga-Etego, I.; Ashagbley, F.; Boadu, E.A.; Dasoberi, I.; Kanyoke, E.; Yabang, E.; Essegbey, I.T.; Adjei, G.A.; Buckle, G.B.; Awoonor-Williams, J.K.; Nang-Beifubah, A.; Twumasi, A.; McCannon, C.J.; Barker, P.M. 2012: A nationwide quality improvement project to accelerate Ghana's progress toward Millennium Development Goal Four: design and implementation progress International Journal for Quality in Health Care: Journal of the International Society for Quality in Health Care 24(6): 601-611
Reddy, B.S.; Damayanthi, Y.; Reddy, B.S.; Lown, J.W. 2000: Design, synthesis and in vitro cytotoxicity studies of novel pyrrolo[2,1-c][1,4]benzodiazepine (PBD)--polymade conjugates and 2,2'-PBD dimers Anti-Cancer Drug Design 15(3): 225-238
Maftouh, M.; Monsarrat, B.; Rao, R.C.; Meunier, B.; Paoletti, C. 1984: Identification of the glucuronide and glutathione conjugates of the antitumor drug N2-methyl-9-hydroxyellipticinium acetate (Celiptium). Comparative disposition of this drug with its olivacinium isomer in rat bile Drug Metabolism and Disposition: the Biological Fate of Chemicals 12(1): 111-119
Kanellos, J.; Pietersz, G.A.; McKenzie, I.F. 1985: Studies of methotrexate-monoclonal antibody conjugates for immunotherapy Journal of the National Cancer Institute 75(2): 319-332
Yeh, H.M.; Su, J.L.; Shiao, K.I.; Lin, S.H.; Chuang, M.W.; Tzeng, C.H.; Chen, P.M. 1988: Preliminary studies on the monoclonal antibody-ricin conjugates Zhonghua Yi Xue Za Zhi 42(6): 417-424
Pietersz, G.A.; Smyth, M.J.; McKenzie, I.F. 1988: Immunochemotherapy of a murine thymoma with the use of idarubicin monoclonal antibody conjugates Cancer Research 48(4): 926-931
Sironi, M.; Canegrati, M.A.; Romano, M.; Vecchi, A.; Spreafico, F. 1984: Chemotherapy-increased antineoplastic effects of antibody-toxin conjugates Cancer Treatment Reports 68(4): 643-645
Vikhrev, N.E.; Zhvirblene, A.A.; Severin, E.S.; Iamnikova, S.S.; L'vov, D.K. 1986: Characteristics of the preparation of monoclonal antibody-based immunoenzyme conjugates Voprosy Virusologii 31(4): 507-509
Guesdon, J.L.; Avrameas, S. 1983: Use of lectin-antibody conjugates for quantitation and titration of antigens and antibodies Methods in Enzymology 92: 489-498
Chang, T.T.; Chou, T.C. 2000: Rational approach to the clinical protocol design for drug combinations: a review Acta Paediatrica Taiwanica 41(6): 294-302
Briejer, M. 2002: Advances in cardiovascular drug development. Biomarkers, surrogates and clinical progress Idrugs: the Investigational Drugs Journal 5(12): 1131-1133
Egorov, S.I.; Krasnovskiĭ, A.A.; Pankovskiĭ, D.B.; Ponomarev, G.V.; Savitskiĭ, A.P. 1990: Photosensitized formation of singlet oxygen in water solutions of covalent porphyrin-antibody conjugates Biulleten' Eksperimental'noi Biologii i Meditsiny 109(4): 349-351
Dosio, F.; Brusa, P.; Delprino, L.; Ceruti, M.; Grosa, G.; Cattel, L.; Bolognesi, A.; Barbieri, L. 1993: A new 'solid phase' procedure to synthesize immunotoxins (antibody-ribosome inactivating protein conjugates) Farmaco 48(1): 105-115
Philpott, G.W.; Bower, R.J.; Parker, K.L.; Shearer, W.T.; Parker, C.W. 1974: Affinity cytotoxicity of tumor cells with antibody-glucose oxidase conjugates, peroxidase, and arsphenamine Cancer Research 34(9): 2159-2164
Siegel, M.B.; Van Swearingen, A.E.D.; Anders, C.K. 2014: Approaches for optimal drug development and clinical trial design for breast cancer brain metastasis Oncology 28(7): 579; 584-585